When to use Blujepa (gepotidacin) for uncomplicated urinary tract infections (uUTIs) in a female patient, 12 years or older, with impaired renal (kidney) or hepatic (liver) function and weighing at least 40 kilograms (kg)?

When to Use Blujepa (Gepotidacin) in Patients with Renal or Hepatic Impairment

Avoid Blujepa (gepotidacin) in patients with severe renal impairment (eGFR <30 mL/min) or severe hepatic impairment (Child-Pugh Class C) due to increased drug exposure and risk of QTc prolongation. 1

Contraindications Based on Organ Function

Severe Renal Impairment (eGFR <30 mL/min)

• Do not use gepotidacin in patients with eGFR <30 mL/min, including those receiving dialysis 1
• The mechanism involves increased gepotidacin plasma concentrations (Cmax), which elevates the risk of dose-dependent QTc interval prolongation 1
• If gepotidacin cannot be avoided in these patients, obtain baseline ECG, monitor and correct serum electrolyte abnormalities, and collect ECGs during treatment as clinically indicated 1

Severe Hepatic Impairment (Child-Pugh Class C)

• Avoid use in patients with severe hepatic impairment (Child-Pugh Class C) 1
• Similar to severe renal impairment, this restriction is based on increased drug exposure and QTc prolongation risk 1
• If administration cannot be avoided, implement the same monitoring strategy: baseline ECG, electrolyte correction, and serial ECG monitoring during treatment 1

Mild to Moderate Renal or Hepatic Impairment

Practical Approach

• The FDA label does not specify dose adjustments or contraindications for mild to moderate renal or hepatic impairment 1
• Patients with mild to moderate impairment who meet other eligibility criteria (female, ≥12 years old, ≥40 kg body weight, uncomplicated UTI with susceptible organisms) may receive standard dosing: 1,500 mg (two 750 mg tablets) orally twice daily for 5 days 1
• Administer after meals to reduce gastrointestinal intolerance 1

Additional Monitoring Considerations

QTc Prolongation Risk Factors

• Beyond renal and hepatic impairment, avoid gepotidacin in patients with: 1
  • History of QTc interval prolongation
  • Pre-existing cardiac disease (arrhythmias, heart failure, structural heart disease)
  • Concomitant use of antiarrhythmic agents or other QTc-prolonging medications
  • Concomitant use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole) which increase gepotidacin exposure 1

Acetylcholinesterase Inhibition

• Monitor patients with conditions that may be exacerbated by acetylcholinesterase inhibition (myasthenia gravis, Parkinson's disease) 1
• Watch for adverse reactions including dysarthria, presyncope, muscle spasms, diarrhea, nausea, vomiting, abdominal pain, hypersalivation, and hyperhidrosis 1
• Exercise caution in patients receiving succinylcholine-type neuromuscular blocking agents, systemic anticholinergic medications, or non-depolarizing neuromuscular blocking agents 1

Clinical Context: Alternative First-Line Agents

Standard First-Line Therapy for uUTI

• For patients with renal or hepatic impairment who cannot receive gepotidacin, consider established first-line agents: 2, 3
  • Nitrofurantoin: Can be used cautiously in patients with eGFR as low as 30 mL/min with close monitoring for treatment failure and adverse effects 4
  • Fosfomycin trometamol: 3 g single dose, recommended only in women with uncomplicated cystitis 3
  • Trimethoprim-sulfamethoxazole: If local resistance patterns show E. coli resistance <20% 2, 3

Treatment Duration

• Treat uncomplicated UTI episodes with as short a duration as reasonable, generally no longer than 7 days 2
• Gepotidacin's 5-day course aligns with this principle 1

Common Pitfalls to Avoid

• Do not assume gepotidacin is safe in severe renal or hepatic impairment simply because it is a newer agent—the FDA label explicitly contraindicates use in these populations 1
• Do not overlook concomitant medications that may interact via CYP3A4 inhibition or QTc prolongation, as these compound the risk in patients with borderline organ function 1
• Do not use gepotidacin in pregnant patients—it is indicated only for non-pregnant females ≥12 years old 1, 5
• Do not forget to obtain urine culture and sensitivity before treatment in patients with recurrent UTIs to guide appropriate antimicrobial selection 2, 3